OncLive - Bringing the Oncology Community Together

Nonalcoholic fatty liver disease, a risk factor linked to the development of hepatocellular carcinoma and increased mortality, is growing in clinical significance. Read More >>

New Myeloma Guidelines Reflect Advances in Imaging, Explosion of Treatment Options

KD025 Hits High Response Rate in Chronic GVHD

Frontline Setting in mRCC Continues to Evolve With Combo Regimens

CDK4/6 Inhibitors Show Unmatched OS Benefit in Metastatic HR+ Breast Cancer

Investigators Link Novel Biomarker to Therapy in DLBCL Trial

View More Stories >>

View Conference Coverage

2019 New York Lung Cancers Symposium

2019 Chemotherapy Foundation Symposium

2019 Hairy Cell Leukemia Foundation Annual Conference

2019 Lynn Sage Breast Cancer Symposium

2019 ESMO Congress

Dr. Backes on Safety Profile of Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

Dr. Hamilton on the Impact of Biosimilars in Oncology

Dr. Jonasch on Modulating the Tumor Microenvironment in RCC

Dr. Yadav on Differences in Type 1 and Type 2 Uterine Cancer

Dr. Stiles on Surgical Considerations in Lung Cancer

Dr. Eng on Unmet Needs in Early-Onset CRC

OncLive houses thousands of videos that provide updates and information.
See more Videos

I/O Combination Strategies in Hepatocellular Carcinoma

$Elevated AFP in Relapsed/Refractory Metastatic HCC$

Elevated AFP in Relapsed/Refractory Metastatic HCC

DLL3-Targeted and Chemo-Sensitive Therapy

PARP Inhibition in BRCA1/2+ or HRD- Ovarian Cancer

Combination Veliparib and Chemotherapy in Ovarian Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

Identifying Rare Mutations in NSCLC

MET as a Driver in NSCLC

Next Steps in Research for BRAF-Mutant NSCLC

TRK Inhibition: Future Challenges and Evolutions

Use of TRK Inhibition in Specific Tumor Types

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured

ESMO Data Show More Can Be Done for Cancer of Unknown Primary Patients

Two research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial (CUPISCO) for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial.

View more >>>

Featured

TRK Inhibitors: Precision Medicine in Oncology

Benjamin Levy, MD; Mark Agulnik, MD; Marcia Brose, MD, PhD; Edward Kim, MD; John Marshall, MD; and Philip Agop Philip, MD, PhD, FRCP, discuss the use of TRK inhibitors in oncology.

View more >>>

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

FDA Approval of a Biosimilar, Promising Data in Myeloma and GBM, and More